W E Evans|M V Relling - JoVE Visualize

Showing results (31-40 of 342) with videos related to

Pageof 35

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994

Patient characteristics associated with high-risk methotrexate concentrations and toxicityM V Relling, D Fairclough, D Ayers, et al.

Pediatric Clinics of North America|October 1, 1989

Clinical pharmacology of cancer chemotherapy in childrenW E Evans, W P Petros, M V Relling, et al.

Pharmacotherapy|January 1, 1992

Variability in teniposide plasma protein binding is correlated with serum albumin concentrationsW P Petros, J H Rodman, M V Relling, et al.

The Journal of Pediatrics|April 1, 1989

Lorazepam pharmacodynamics and pharmacokinetics in childrenM V Relling, R K Mulhern, R K Dodge, et al.

Blood|July 15, 1994

Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemiaJ C Barredo, T W Synold, J Laver, et al.

Leukemia|January 1, 1996

Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemiaE Masson, T W Synold, M V Relling, et al.

Nature Reviews. Cancer|March 22, 2002

Pharmacogenetics and cancer therapyM V Relling, T Dervieux

NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.

Human Molecular Genetics|June 1, 1994

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeR Saxena, G L Shaw, M V Relling, et al.

Medical and Pediatric Oncology|January 1, 1991

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.

Pageof 35

Showing results (31-40 of 342) with videos related to

Sort By:

Pageof 35

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994

Patient characteristics associated with high-risk methotrexate concentrations and toxicityM V Relling, D Fairclough, D Ayers, et al.

Pediatric Clinics of North America|October 1, 1989

Clinical pharmacology of cancer chemotherapy in childrenW E Evans, W P Petros, M V Relling, et al.

Pharmacotherapy|January 1, 1992

Variability in teniposide plasma protein binding is correlated with serum albumin concentrationsW P Petros, J H Rodman, M V Relling, et al.

The Journal of Pediatrics|April 1, 1989

Lorazepam pharmacodynamics and pharmacokinetics in childrenM V Relling, R K Mulhern, R K Dodge, et al.

Blood|July 15, 1994

Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemiaJ C Barredo, T W Synold, J Laver, et al.

Leukemia|January 1, 1996

Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemiaE Masson, T W Synold, M V Relling, et al.

Nature Reviews. Cancer|March 22, 2002

Pharmacogenetics and cancer therapyM V Relling, T Dervieux

NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.

Human Molecular Genetics|June 1, 1994

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeR Saxena, G L Shaw, M V Relling, et al.

Medical and Pediatric Oncology|January 1, 1991

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.

Pageof 35